| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
| Targets |
The primary targets of 2,6-Dihydroxyacetophenone include reactive oxygen species, as it has demonstrated antioxidant activity. The compound also targets inflammatory pathways, exhibiting anti-inflammatory properties. It has antimicrobial activity against various bacterial and fungal pathogens. These targets make it relevant for research in oxidative stress, inflammation, and infectious diseases.
|
|---|---|
| ln Vitro |
In vitro, 2,6-Dihydroxyacetophenone demonstrates antioxidant activity by scavenging free radicals. It exhibits anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines and mediators. The compound also shows antimicrobial activity against various bacterial and fungal strains. These in vitro activities support its use in antioxidant, anti-inflammatory, and antimicrobial research.
|
| ln Vivo |
In vivo, 2,6-Dihydroxyacetophenone has potential applications as an antioxidant, anti-inflammatory, and antimicrobial agent. However, detailed in vivo efficacy data are limited. The compound is a natural product found in various plants and may have physiological functions. Further studies are needed to evaluate its therapeutic potential in animal models.
|
| Enzyme Assay |
In vitro antioxidant assays for 2,6-Dihydroxyacetophenone include DPPH, ABTS, and FRAP radical scavenging assays. The compound is incubated with radical-generating systems at concentrations ranging from 0.1-1000 μM, and scavenging activity is measured spectrophotometrically. Anti-inflammatory activity is assessed by measuring cytokine production in activated macrophages. Antimicrobial activity is assessed using broth microdilution methods. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for 2,6-Dihydroxyacetophenone are conducted using macrophages, cancer cell lines, or other relevant cell types. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. ROS levels are measured using fluorescent probes. Inflammatory cytokine production is assessed by ELISA. Cell viability is assessed using MTT assays. Experiments include vehicle controls and positive controls.
|
| Animal Protocol |
In vivo animal studies with 2,6-Dihydroxyacetophenone are limited, as the compound is primarily used as a research tool. Anti-inflammatory studies may be conducted in models of acute inflammation. The compound is administered via intraperitoneal or oral routes at doses ranging from 1-50 mg/kg. Each group consists of 6-10 animals with vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,6-Dihydroxyacetophenone have not been extensively characterized. As a small, polar molecule, it is expected to have moderate oral bioavailability. Metabolism likely occurs through conjugation (glucuronidation and sulfation), with elimination via renal excretion. Detailed PK parameters require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,6-Dihydroxyacetophenone indicate that it is generally well-tolerated at research doses. No significant toxicity has been reported. As with all research chemicals, appropriate safety precautions should be taken during handling.
|
| Additional Infomation |
2',6'-Dihydroxyacetophenone is an aromatic ketone. It has been reported to exist in Daldinia eschscholtzii, Euphorbia lunulata, and other organisms with relevant data.
2,6-Dihydroxyacetophenone is a dihydroxyacetophenone derivative with antioxidant, anti-inflammatory, and antimicrobial activities. It is a natural product found in various plants and is used as a chemical intermediate in organic synthesis. The compound is used in research on oxidative stress, inflammation, and infectious diseases. Not approved for clinical therapeutic use; intended for research purposes only. |
| Molecular Formula |
C₈H₈O₃
|
|---|---|
| Molecular Weight |
152.15
|
| Exact Mass |
152.047
|
| CAS # |
699-83-2
|
| PubChem CID |
69687
|
| Appearance |
Solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
262.8±20.0 °C at 760 mmHg
|
| Melting Point |
156-158 °C(lit.)
|
| Flash Point |
127.0±18.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
2.28
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
145
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YPTJKHVBDCRKNF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H8O3/c1-5(9)8-6(10)3-2-4-7(8)11/h2-4,10-11H,1H3
|
| Chemical Name |
1-(2,6-dihydroxyphenyl)ethanone
|
| Synonyms |
2,6Dihydroxyacetophenone; 2,6 Dihydroxyacetophenone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~657.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5725 mL | 32.8623 mL | 65.7246 mL | |
| 5 mM | 1.3145 mL | 6.5725 mL | 13.1449 mL | |
| 10 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
